Biogen (BIIB34) Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. More details

BIIB34 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 26.6% below our estimate of its fair value

Earnings are forecast to grow 22.09% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Profit margins (8.3%) are lower than last year (15.3%)

BIIB34 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW463,909 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

463,909 investors already sharing narratives

View all narratives

Biogen Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biogen
Historical stock prices
Current Share Price	US$188.29
52 Week High	US$191.00
52 Week Low	US$120.36
Beta	0.16
1 Month Change	10.54%
3 Month Change	16.30%
1 Year Change	47.86%
3 Year Change	-12.76%
5 Year Change	-37.61%
Change since IPO	12.16%

Recent updates

Shareholder Returns

	BIIB34	BR Biotechs	BR Market
7D	9.0%	4.8%	0.2%
1Y	47.9%	25.2%	9.8%

Return vs Industry: BIIB34 exceeded the BR Biotechs industry which returned 25.8% over the past year.

Return vs Market: BIIB34 exceeded the BR Market which returned 12.1% over the past year.

Price Volatility

Is BIIB34's price volatile compared to industry and market?
BIIB34 volatility
BIIB34 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.3%
Market Average Movement	4.2%
10% most volatile stocks in BR Market	8.1%
10% least volatile stocks in BR Market	1.8%

Stable Share Price: BIIB34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine BIIB34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1978	7,500	Chris Viehbacher	www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB34 fundamental statistics
Market cap	R$164.49b
Earnings (TTM)	R$4.33b
Revenue (TTM)	R$52.08b

37.9x

P/E Ratio

3.2x

P/S Ratio

Is BIIB34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIB34 income statement (TTM)
Revenue	US$10.03b
Cost of Revenue	US$2.17b
Gross Profit	US$7.85b
Other Expenses	US$7.02b
Earnings	US$834.60m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	5.65
Gross Margin	78.32%
Net Profit Margin	8.32%
Debt/Equity Ratio	42.9%

How did BIIB34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/21 20:47
End of Day Share Price	2026/08/20 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biogen Inc. is covered by 60 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Biogen (BIIB34) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Biogen Inc. Competitors

Blau Farmacêutica

Biomm

Incyte

Celltrion

Price History & Performance

Recent News & Updates

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others.

Bioarctic AB Partner Eisai Receives Fda Approval for Leqembi Iqlik Subcutaneous Injection as Starting Dose for Early Alzheimer's Disease

Biogen Inc. Appoints Michael J. Parini as Chief Legal Officer, Effective August 3, 2026

Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026

Eisai Co., Ltd. And Biogen Inc. Receive FDA Approval For LEQEMBI IQLIK Subcutaneous Injection As Initiation Dose For Early Alzheimer’s Disease

Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease

Recent updates

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others.

Bioarctic AB Partner Eisai Receives Fda Approval for Leqembi Iqlik Subcutaneous Injection as Starting Dose for Early Alzheimer's Disease

Biogen Inc. Appoints Michael J. Parini as Chief Legal Officer, Effective August 3, 2026

Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026

Eisai Co., Ltd. And Biogen Inc. Receive FDA Approval For LEQEMBI IQLIK Subcutaneous Injection As Initiation Dose For Early Alzheimer’s Disease

Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease

Biogen To Present New Data Across Its Alzheimer’s Disease Portfolio At AAIC 2026

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion.

Biogen Inc. to Report Q2, 2026 Results on Jul 29, 2026

Biogen Receives FDA Breakthrough Therapy Designation for Salanersen for Spinal Muscular Atrophy

Biogen Inc. and Denali Therapeutics Inc. Provide Update on Phase 2b LUMA Study Of BIIB122 In Early-Stage Parkinson’s Disease

Biogen Announces Topline Results from Phase 2 Celia Study of Diranersen

Biogen Announces Topline Results from Phase 2 Celia Study of Diranersen (Biib080)

Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease

Biogen Inc. to Report Q1, 2026 Results on Apr 29, 2026

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) from The Morningside Group Limited and others for $5.6 billion.

Biogen Inc. Announces Approval Of High Dose Regimen Of Spinraza For Spinal Muscular Atrophy

Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus

Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States

Block & Leviton LLP Announces United States District Court for the District of Massachusetts Certifies Class Action on Behalf of Purchasers of Biogen, Inc. Securities

Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026

Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Biogen Inc., Annual General Meeting, Jun 09, 2026

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment Options

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen Inc. to Report Q4, 2025 Results on Feb 06, 2026

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Eisai Co., Ltd. and Biogen Inc. Present New Data

Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

Biogen to Highlight New Lecanemab Data and Scientific Advances At the 18Th Clinical Trials on Alzheimer's Disease Conference

Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2025 Results on Oct 30, 2025

Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in Australia

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025

Biogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Biogen Inc. to Report Q2, 2025 Results on Jul 31, 2025

Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus

Biogen Inc., Annual General Meeting, Jun 17, 2025

Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European Union

BioPharma Credit PLC Enters into Settlement Agreement with Biogen

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen Inc. Provides Earnings Guidance for the Full Year 2025

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External Innovation

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico